AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04813185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging the Gap
Description: Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices.
Study NCT05099640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Study NCT05099640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to PTC923
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 1 mg/kg IV
Description: Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 3 mg/kg IV
Description: Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 10 mg/kg IV
Description: Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 20 mg/kg IV
Description: Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 40 mg/kg IV
Description: Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT05315921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrhAAT 60 mg/kg IV
Description: Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study NCT06148558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen Moisturizer
Description: A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
Study NCT06148558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Cleansing Lotion
Description: A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
Study NCT06148558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Facial Moisturizer
Description: A provided facial moisturizer (Goodier) was used 1x daily (PM).
Study NCT05047276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AloCelyvir
Description: Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
Study NCT05835479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Trimoxazole
Description: Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Study NCT05835479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin Acetate / Co Trimoxazole
Description: Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Study NCT05707923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linguistic simplification
Description: Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
Study NCT06471270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histologic evaluation
Description: histologic evaluation
Study NCT06471270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biochemical analysis
Description: IL-6, IL-8 and sCD44
Study NCT06471270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination
Description: clinical examination
Study NCT04931992 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis
Study NCT04931004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash Product
Description: Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
Study NCT04931004 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water rinse
Description: 30-second water rinse will occur in the control group. Viral load will be measured prior to and after water rinse using serial face mask and saliva samples.
Study NCT05271513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )
Description: repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
Study NCT05271513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation
Description: sham trans-spinal magnetic stimulation
Study NCT04750551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study NCT04750551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: EStim will applied for 10 to 20 minutes.
Study NCT05018234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noval Oral Appliance
Description: A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
Study NCT05722665 — intervention group
Intervention type: OTHER
Intervention: Categorization of chest xrays images
Description: Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
Study NCT04776590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: neoadjuvant immunotherapy
Study NCT04673786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P43
Description: 45mg or 90mg dose subcutaneous administration
Study NCT04673786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P43
Description: 45mg or 90mg dose subcutaneous administration
Study NCT04673786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: 45mg or 90mg dose subcutaneous administration
Study NCT06099587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high-resolution diffusion MRI
Description: The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
Study NCT05514964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility study
Description: Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures.
Study NCT05040308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrating PrEP delivery
Description: Integration of PrEP delivery services in NSP and MAT programs
Study NCT05838638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSSET-CINV
Description: Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
Study NCT05838638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSSET-CINV
Description: Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
Study NCT06542315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid hormone (IOPTH) monitoring
Description: Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.
Study NCT05220605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BromAc
Description: Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
Study NCT05421910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic training combined with electrical stimulation
Description: Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
Study NCT05421910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: robotic training combined with electrical stimulation
Description: Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
Study NCT04301141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Cognitive Behavioural Therapy
Description: The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
Study NCT04937088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Liquid aspirin formulation
Study NCT04937088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA
Description: Liquid aspirin formulation
Study NCT04884048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographs
Description: Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
Study NCT06146725 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor resection
Description: Maximal safe resection of the tumor
Study NCT06146725 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Biopsy of the tumor
Study NCT06426069 — intervention group
Intervention type: OTHER
Intervention: Masticatory efficiency assessment
Description: Masticatory efficiency will be assessed for each group.
Study NCT06095856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaf Gauge
Description: Occlusal device used to locate centric relation of the jaws
Study NCT06095856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucia Jig
Description: Occlusal device used to locate centric relation of the jaws
Study NCT06095856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kois Deprogrammer
Description: Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
Study NCT04086550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIQOSEAL
Description: Adjunctive bioresorbable patch
Study NCT04086550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal, Adherus
Description: synthetic absorbable sealants
Study NCT06424093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
Study NCT06424093 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Technology
Description: To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
Study NCT05051007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
Study NCT05051007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
Study NCT05272033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study NCT05272033 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Transcutaneous Electrical Acupoint Stimulation
Study NCT05079607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitopure Topical Formula 1
Description: topical skin cream containing the low dose mitophagy activator Mitopure
Study NCT05079607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitopure Topical Formula 2
Description: topical skin cream containing the high dose mitophagy activator Mitopure
Study NCT05155501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted radical prostatectomy (RP)
Description: The conventional approach to prostate cancer surgery
Study NCT05155501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)
Description: A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate.
Study NCT05300516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vagus nerve-guided group
Description: The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
Study NCT05242783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
Study NCT05242783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
Study NCT06448208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: positron emission tomography (PET) scans
Description: Before and after treatment.
Study NCT05110976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
Study NCT05110976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
Study NCT05350059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU) to the Breast Cancer
Description: Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
Study NCT04997057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics mixture
Description: 12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~* Bifidobacterium longum LA 101~* Lactobacillus helveticus La 102~* Lactococcus lactis LA 103~* Streptococcus thermophilus LA 104
Study NCT05218616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aviga, capsules 50 mg / Sutent®, capsules 50 mg
Description: Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
Study NCT05218616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sutent®, capsules 50 mg / Aviga, capsules 50 mg
Description: Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
Study NCT04732507 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 1% plain lidocaine and 0.25% plain bupivacaine
Description: A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
Study NCT05361720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT05361720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT05361720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05593887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip reconstruction surgery.
Description: This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
Study NCT05593887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femoral resection
Description: Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
Study NCT05593887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femoral valgus ostetomy
Description: The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
Study NCT06099938 — intervention group
Intervention type: DRUG
Intervention: sufentanil, ropivacaine
Description: The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
Study NCT05692388 — intervention group
Intervention type: OTHER
Intervention: Patient and Community Stakeholder Interviews
Description: Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
Study NCT05692388 — intervention group
Intervention type: OTHER
Intervention: Cross-sectional Study Participants
Description: Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.